Eckert & Ziegler boosts early phase offering with Vitalea Science takeover

Isotope tech firm Eckert & Ziegler buys bioanalytical CRO Vitalea
Isotope technology firm Eckert & Ziegler has acquired bioanalytical CRO Vitalea Science.

The deal - terms of which were not disclosed - adds Vitalea’s range of accelerator mass spectrometry (AMS) technologies and preclinical and early phase clinical services to Eckert & Ziegler’s offering.

Frank Yeager, president and CEO of Eckert & Ziegler Isotope Products, said: "Vitalea is a unique company with a very unique capability built around the BioMICADAS device, which is the state-of-the-art in AMS technology. We believe that this capability will both allow Eckert & Ziegler to add value to our existing customer base and expand our area of expertise in new markets."

This was echoed by Bob Bethem, president and CEO at Vitalea Science, who said that: “The acquisition of Vitalea Science by Eckert & Ziegler helps to provide the commercial strength of EZAG to the technical prowess of Vitalea."

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars